How much cosentyx is injected per psoriasis treatment?

How much Cosentyx is used for psoriasis

Cosentyx (secukinumab) comes in 150 mg prefilled syringes or pens. For moderate to severe plaque psoriasis, the standard regimen starts with weekly injections for the first five weeks: 300 mg per dose delivered as two 150 mg injections at week 0, 1, 2, 3, and 4. After the loading phase, patients move to once-monthly maintenance at 300 mg.

For patients weighing under 90 kg who show adequate response at 150 mg, some clinicians keep them on the lower dose throughout.

What happens if a patient misses a dose

Missing a dose requires immediate contact with the healthcare provider. The missing injection is taken as soon as possible, then the schedule resumes at the monthly cadence. The manufacturer does not recommend doubling doses to catch up.

Why is Cosentyx preferred over some other biologics for psoriasis

Cosentyx targets interleukin-17A directly, a cytokine that drives skin inflammation in plaque psoriasis. Compared with TNF inhibitors such as Humira or Enbrel, Cosentyx shows higher skin-clearance rates in head-to-head studies. In clinical trials, roughly 80 percent of patients reached PASI 75 at week 12 after the 300 mg regimen.

Can biosimilars enter before Cosentyx patents expire

Cosentyx has composition-of-matter protection until at least 2027 in the United States, plus additional patents covering formulations and methods of use. [1] Biosimilars are unlikely to launch before then.

When does Cosentyx exclusivity expire

Exclusivity granted by the FDA runs through January 2025 for certain claims, but core patent coverage extends further. [1]

Why are companies challenging this patent

Generic and biosimilar manufacturers have filed inter partes reviews and petitioned for patent invalidity at the USPTO. The challenges center on obviousness claims and lack of enablement for the breakeven 300 mg versus 150 mg dosing distinction.

How does Cosentyx compare with Keytruda

Cosentyx is a monoclonal antibody targeting IL-17A for skin and joint conditions, while Keytruda is a PD-1 checkpoint blocker for oncology. They serve völlig different therapeutic areas and therefore do not overlap in comparison.

How does Cosentyx compare with Skyrizi

Skyrizi (risankizumab) also belongs to the IL-23 pathway rather than the IL-17 pathway. In indirect comparisons, both drugs reach similar PASI 90 rates at week 12, but Cosentyx has a faster onset of action.